Orbital tumor in DICER1 syndrome (embryonal tumor with multilayered rosettes) successfully treated with intraarterial chemotherapy Authors: David H. Abramson, Leonard Wexler, Michelle Maeng, Juan C. Vasquez, David Della Rocca, Jasmine H. Francis, Lisa Koenig, Jamal Benhamida, Marc Rosenblum, Y. Pierre Gobin Published: 2026 ABSTRACT PurposeOphthalmic malignancies are well described in DICER1 syndrome and include intraocular malignancies and, rarely, primary orbital tumors (or medulloepitheliomas). Here, we present the case of an aggressive primary orbital malignancy (embryonal tumor with multilayered rosettes [ETMR]) in a child with germline and somatic DICER1 abnormalities.ObservationsIn a 1-month-old boy born at term, a computed tomography scan revealed an orbital mass initially thought to be consistent with a capillary hemangioma. After initial treatment with a 4-week course of oral propranolol (3 mg/kg/day) without response, a magnetic resonance imaging scan revealed an enlarging lobulated large enhancing left intraconal mass. A series of biopsies and DNA methylation array analyses showed the lesion to be an ETMR, atypical subclass. Germline analysis revealed a mutation in the DICER1 gene. The tumor itself had a second, different mutation in the DICER1 gene. ETMR has been rarely identified in the orbit and there are no accepted treatments, but overall survival of ETMR lesions is poor (<20%) with combinations of surgery, radiation, or brachytherapy. The family was offered exenteration but refused, so intraarterial chemotherapy was offered with the understanding that it had never been tried in DICER1-mutated orbital ETMR. After treatment in 4 monthly 2-h outpatient sessions with intraarterial chemotherapy, we observed prompt regression of clinical findings. Serial imaging following the final cycle of treatment demonstrated no evidence of recurrent or progressive disease. Twenty-three months later, there has been no regrowth.Conclusion and importanceA somatic and germline (“two hit”) DICER1-mutated orbital tumor was successfully managed without surgery, radiation, or systemic chemotherapy using the well-established intraarterial approach presently used for retinoblastoma. In the case of our patient, intraarterial chemotherapy proved to be an effective treatment for this tumor. Introduction Ophthalmic malignancies are well described in DICER1 syndrome. They include intraocular malignancies (medulloepitheliomas)1, 2, 3, 4, 5 and, rarely, primary orbital tumors (classified in the past as medulloepitheliomas).2 In addition, intraocular medulloepitheliomas can present as orbital tumors. In either, metastases and death are common.3,4 Although a DICER1-mutated embryonal tumor with multilayered rosettes (ETMR) in a patient with germline and somatic DICER1 mutations has not been previously reported, ETMR of the orbit have been rarely reported.6 There is no accepted management, but overall ETMR has a low survival rate despite radiation, chemotherapy, and/or surgery (<20%).6 Here, we present a case of an aggressive primary orbital malignancy in a child with germline and somatic DICER1 abnormalities whom we have treated with intraarterial chemotherapy (ophthalmic artery chemosurgery). The child remains free of disease 15 months after treatment. Case presentation We were asked to evaluate a healthy 1-month-old boy born at term after an uncomplicated pregnancy, labor, and delivery for rapidly progressing proptosis, noted to be increasing daily according to the parents (Fig. 1, left). A computed tomography scan revealed an orbital mass initially thought to be consistent with a capillary hemangioma, and the child was treated with a 4-week course of oral propranolol (3 mg/kg/day) without response. A subsequent magnetic resonance imaging scan revealed an enlarging lobulated large enhancing left intraconal mass that measured 2.4× 2.6 cm axially. The mass demonstrated diffusion restriction and T1/T2 isointensity with peripheral nonenhancing components. There was mass effect on the recti muscles, which were displaced and stretched. The mass encased the left intraorbital optic nerve (Fig. 1, right).Fig. 1External photograph (left) and initial magnetic resonance imaging scan (right) of orbit prior to treatment. The intraconal mass measured 2.4 × 2.6 axially with diffusion restriction. External photograph (left) and initial magnetic resonance imaging scan (right) of orbit prior to treatment. The intraconal mass measured 2.4 × 2.6 axially with diffusion restriction. An initial incisional biopsy sample demonstrated a small round blue cell tumor. A second, larger biopsy showed tumor cells forming, in addition to sheets, perivascular pseudorosettes, and true pseudostratified rosettes with areas of neuropil-like matrix production, revealed by a representative hematoxylin and eosin section (Fig. 2). DNA methylation array analysis using v12.8 of the Heidelberg classifier showed the lesion to match at high confidence (calibrated score: 0.9999) to an ETMR, atypical (c19mc-non-altered) subclass. The tumor clustered with this subclass on UMAP analysis, and the array-generated copy number plot demonstrated broad gains across chromosome 2. Next-generation sequencing demonstrated both a pathogenic, somatic DICER1 variant in the tumor DNA (p.D1709Y, c.5125G > T) and a heterozygous, pathogenic germline DICER1 variant (p.Ile1711Phefs*6, c.5130delG) that was also detected in the father (who had never had cancer). ARCHER gene fusion analysis was negative. Staging studies, whole-body positron emission tomography–computed tomography, and chest computed tomography revealed no distant metastases. The patient was treated in 4 monthly 2-h outpatient sessions during which intraarterial chemotherapy (melphalan, topotecan, and carboplatin) was delivered into the ophthalmic artery with a 450-μm microcatheter positioned at the ostium of the take-off of the ophthalmic artery each treatment session. The doses were melphalan 2.5 mg, topotecan 2 mg, and carboplatin 35 mg for cycles 1 and 2; and melphalan 2.5 mg and carboplatin 35 mg for cycles 3 and 4. Grade III hematologic toxicity developed after three sessions (no transfusion or fever/neutropenia). The parents noted regression of the proptosis within two weeks and a month later (Fig. 3, left), magnetic resonance imaging confirmed a shrunken, nonviable residual with no diffusion restriction or increase with contrast. The mass measured 1.6 × 0.9 cm axially. (Fig. 3, right). Monthly imaging following the final cycle of treatment demonstrated no evidence of recurrent or progressive disease. Fifteen months later there has been no regrowth.Fig. 2Tumor cells lie in a neuropil-like matrix and form a multilayered rosette at top right (hematoxylin and eosin stain, 20×).Fig. 3External photograph (left) and magnetic resonance imaging scan (right) one year after treatment. The mass measures 1.6 × 0.9 cm axially with no diffusion restriction or increase with contrast. Tumor cells lie in a neuropil-like matrix and form a multilayered rosette at top right (hematoxylin and eosin stain, 20×). External photograph (left) and magnetic resonance imaging scan (right) one year after treatment. The mass measures 1.6 × 0.9 cm axially with no diffusion restriction or increase with contrast. Discussion DICER1 syndrome was initially described in 2009 and is now recognized as the first cancer syndrome that is caused by a defect in microRNA processing.7 Patients with germline DICER1 syndrome are at risk for developing many cancers, notably pleuropulmonary blastoma, Sertoli-Leydig tumor, cervical embryonal rhabdomyosarcoma, and bladder rhabdomyosarcoma. Benign tumors have also been associated with the syndrome, including cystic nephroma, follicular thyroid nodular disease, and benign lung cystic lesions. Rarely, pituitary blastoma, pineoblastoma, Wilms tumor, and hamartomas such as chondromesenchymal nasal hamartomas and juvenile hamartomatous intestinal polyps have also been reported. A complete listing of all benign and malignant tumors associated with the syndrome can be found elsewhere,8 and the ocular phenotype of the syndrome has been well characterized.9 Although DICER1 syndrome is an autosomal dominant localized to chromosome 14q32.13 (27 exons/1922 amino acids) and requires two hits (as in our patient), it is not a classic tumor suppressor; boys develop manifestations more commonly than girls, and 87% are inherited from a parent (13% de novo).8 Interestingly, the majority of non-inherited patients with the syndrome appear to be mosaics. The most notable of the lesions, pleuropulmonary blastoma, develops early (8 months of age). As there is potential morphologic overlap between medulloepitheliomas and ETMR,10,11 it is conceivable that at least some ocular medulloepitheliomas complicating DICER1 mutation actually represent ETMRs12; the subject has not been studied in the rare primary orbital tumors thought to be medulloepitheliomas. This patient presented in early infancy with a rapidly enlarging, histologically aggressive but radiographically localized orbital mass. Considerations for management included the administration of conventional, intravenous cytotoxic chemotherapy, orbital exenteration, or both. Following extensive discussions with the parents, and based on the uncertain metastatic potential of this entity and the unacceptable nature of conventional surgical options regarding quality of life, a trial of intraarterial chemotherapy was commenced and led to rapid and dramatic disease regression, and sustained (15+ months) apparent disease control with intact vision in the affected eye. After conducting a literature review on August 10, 2026, utilizing PubMed and Google Scholar using the key words DICER1, ETMR, and intraarterial chemotherapy, we found fewer than 10 cases of DICER1-mutant ETMR cases documented in the literature,13 and none of those patients were identified with an orbital lesion or treated with primary intraarterial chemotherapy (also called ophthalmic artery chemosurgery) for any orbital tumor in the DICER1 germline sphere. This technique was introduced at Memorial Sloan Kettering Cancer Center in 200612 for intraocular retinoblastoma and is now the preferred management for unilateral retinoblastoma worldwide. It has eliminated 95% of all enucleations.14 The technique has been described in detail previously.15 Briefly, as an outpatient and under general anesthesia, a microcatheter (450 μm) is introduced into the femoral artery, threaded up to the internal carotid artery (bypassing the heart) and further advanced into the one blood vessel supplying the eye: the ophthalmic artery. Then, the chemotherapy drug(s) are infused in a pulsatile fashion over 10–30 minutes (approximately 10 minutes of infusion for each drug). The average patient with retinoblastoma receives three treatments, each a month apart, and the outpatient procedure lasts 2 h including anesthesia time. Patient survival is over 99% and ocular survival 95%.15 The ophthalmic artery also supplies the orbit including the optic nerve, extraocular muscles, fat, and parts of the upper lid. In our case, the blood supply to the tumor was also from the same ophthalmic artery, so treatment was similar to the established retinoblastoma protocol. The child tolerated the procedure well, did not require prophylactic antibiotics or transfusion of any blood product, and did not develop fever/neutropenia. Our approach avoided multiagent systemic chemotherapy, radiation, and disfiguring surgery without affecting vision. CRediT authorship contribution statement David H. Abramson: Writing – review & editing, Writing – original draft, Resources, Investigation, Funding acquisition, Conceptualization. Leonard Wexler: Writing – review & editing, Visualization, Supervision, Data curation. Michelle Maeng: Writing – review & editing, Resources, Data curation. Juan C. Vasquez: Writing – review & editing, Resources, Data curation. David Della Rocca: Writing – review & editing, Resources, Data curation. Jasmine H. Francis: Writing – review & editing, Funding acquisition. Lisa Koenig: Writing – review & editing, Visualization, Data curation. Jamal Benhamida: Writing – review & editing, Visualization, Data curation. Marc Rosenblum: Writing – review & editing, Visualization, Resources, Data curation. Y. Pierre Gobin: Writing – review & editing, Resources, Investigation, Data curation, Conceptualization. Patient consent The patient's legal guardians completed a consent form to have the patient's information shared for this case report. Authorship All authors attest that they meet the current ICMJE criteria for authorship. Data statement Data may be made available upon reasonable request to the corresponding author. Funding Supported by the Fund for Ophthalmic Knowledge Inc. Declaration of competing interest L.W. reports consulting fees from US World Medicine; M.M. reports travel support from Yale; J.B. reports attending an event sponsored by Illumina Inc. where they provided food. The following authors have no financial disclosures: D.H.A., J.C.V., D.D.R., J.H.F., L.K., M.R., Y.P.G.